human cervix cancer hela cells  (ATCC)

Journal: Cell Death Discovery

Article Title: Mitochondria-targeted antioxidant MitoQ radiosensitizes tumors by decreasing mitochondrial oxygen consumption

doi: 10.1038/s41420-024-02277-9

Figure Lengend Snippet: a – c Cancer cells were treated with increasing doses of MitoQ for 24 h, and the oxygen consumption rate (OCR) of 10 000 cells/well was measured using Seahorse oximetry. Left graphs represent total OCR measurements over time. From Seahorse traces, basal, maximal and ATP-linked mitochondrial OCRs (mtOCRs) were calculated and are displayed on the right. a SiHa human cervix cancer cells were tested ( n = 4). b PC3 human prostate cancer cells were tested ( n = 4). Full mtOCR inhibition was reached at 250 nM MitoQ (arrow). c HCT116 human prostate cancer cells were tested ( n = 4). Full mtOCR inhibition was reached at 250 nM MitoQ (arrow). All data are shown as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.005 by one-way ANOVA with Dunnett’s multiple comparisons test.

Article Snippet: MCF7 (American Type Culture Collection [ATCC], Manassas, VA, USA; catalog #HTB-22) and MDA-MB-231 (ATCC, catalogue #HTB-26) human breast adenocarcinoma cancer cells, SiHa human cervix cancer cells (ATCC, catalog #HTB-35), PC3 human prostate cancer cells (ATCC, catalog #CRL-1435) and HCT116 human colon cancer cells (ATCC, catalog #CCL-247) were cultured at 37 °C in a 5% CO 2 humidity-controled incubator in DMEM containing GlutaMAX, 4.5 g/L D -glucose without pyruvate (ThermoFisher Scientific, Dilbeek, Belgium; catalogue #10566016), supplemented with 10% FBS (Sigma-Aldrich, Overijse, Belgium).

Techniques: Inhibition

Journal: Cell Death Discovery

Article Title: Mitochondria-targeted antioxidant MitoQ radiosensitizes tumors by decreasing mitochondrial oxygen consumption

doi: 10.1038/s41420-024-02277-9

Figure Lengend Snippet: a MCF7 breast cancer cells were treated ± 500 nM MitoQ for 24 h and subjected to subcellular fractionation. Mitochondrial and cytosolic ATP were measured using a fluorescence assay and are reported in the left and right graphs, respectively ( n = 3). b MCF7 cells were treated with increasing doses of MitoQ for 24 h, and ΔΨ was measured via JC-10 fluorescence ( n = 6). c Glucose consumption and lactate production rates were measured in MCF7 cells pretreated for 24 h ± 500 nM MitoQ ( n = 6). d As in (a) but using MDA-MB-231 cancer cells treated ± 250 nM MitoQ ( n = 3). e As in (b) but using MDA-MB-231 cells ( n = 6). f As in c but using MDA-MB-231 cancer cells treated ± 250 nM MitoQ ( n = 6). g Seahorse XF cell energy map of cancer cells plotted by their basal OCR and basal extracellular acidification rate (ECAR) before and 24 h after treatment with MitoQ at the concentrations identified to bring ATP production linked to mtOCR to 0 (SiHa, 1 µM; MCF7, 500 nM; MDA-MB-231, 250 nM; PC3, 250 nM; HCT116, 250 nM) ( n = 4–6). All data are shown as means ± SEM. ns P > 0.05, ** P < 0.01, *** P < 0.005 compared to untreated controls; by one-way ANOVA with Tukey’s multiple comparisons test ( a, b, d, e ) or Student’s t test ( c, f ).

Article Snippet: MCF7 (American Type Culture Collection [ATCC], Manassas, VA, USA; catalog #HTB-22) and MDA-MB-231 (ATCC, catalogue #HTB-26) human breast adenocarcinoma cancer cells, SiHa human cervix cancer cells (ATCC, catalog #HTB-35), PC3 human prostate cancer cells (ATCC, catalog #CRL-1435) and HCT116 human colon cancer cells (ATCC, catalog #CCL-247) were cultured at 37 °C in a 5% CO 2 humidity-controled incubator in DMEM containing GlutaMAX, 4.5 g/L D -glucose without pyruvate (ThermoFisher Scientific, Dilbeek, Belgium; catalogue #10566016), supplemented with 10% FBS (Sigma-Aldrich, Overijse, Belgium).

Techniques: Fractionation, Fluorescence